Transgene Provides Business and Financial Update for Q1 2026
…
Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) – Topline data expected by the end of Q1 2028 as per plan
Phase 1 data from TG4050 in head and neck cancer published on medRxiv
License agreement signed with NEC Bio … [10540 chars]
Source: GlobeNewswire | Published: 2026-04-29T15:45:00Z
Credit: GlobeNewswire
